Hi, does anyone have some information about Hu3f8-BsAb trial in MSKCC? From the brief information I get, it is more potent then the previous Hu3f8 (naxitamab) because it is tageting 2 antibodies/ bispesific antibodies especially for relapse and refractory case.
2 Likes